Dr. Joanne Waldstreicher serves as a director of BD (Becton Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. Dr. Waldstreicher has been a member of the board since 2023.
From 2012 to 2023, Dr. Waldstreicher served as the chief medical officer of Johnson & Johnson (J&J), where she provided visionary strategic and operational leadership, with global responsibility for safety, epidemiology, regulatory and clinical operations transformation, bioethics and late-stage pipeline program review. From 2009 to 2012, Dr. Waldstreicher served as chief medical officer at Janssen Pharmaceutical Research and Development, a division of J&J. Prior to this role, she served as vice president and as senior vice president of Global Drug Development at Janssen from 2002 to 2009. Prior to J&J, she led endocrinology and metabolism clinical research at Merck Research Laboratories.
Dr. Waldstreicher has authored more than 55 research publications, holds numerous patents and has established herself as a thought leader in evidence and science-based product development and decision-making, driven by patient needs and bioethical values. Dr. Waldstreicher serves as a director of Structure Therapeutics Inc. and an advisory board member of the Brooklyn College Cancer Center. She also serves on an expert panel for the Reagan Foundation for the U.S. Food and Drug Administration (FDA) and is a faculty affiliate of the Division of Medical Ethics, Department of Population Health at New York University School of Medicine.
Dr. Waldstreicher brings to the board more than 30 years of experience in clinical and strategic leadership, along with a deep knowledge of the healthcare industry and regulatory and safety expertise.